TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism. The company's offerings include drug production and medical research and experimental development, with a pipeline of products such as Rifasutenizole (TNP-2198) for treatment of Helicobacter pylori infection; Rifaquizinone (TNP-2092) injection for treatment of Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and Left ventricular assist device (LVAD) infection; and TNP-2092 oral for treatment of diseases associated with gut bacterial metabolism, including Hepatic encephalopathy (HE) and Irritable bowel syndrome with diarrhea (IBS-D). The company's products under development include TNP-2092 topical for drug-resistant bacterial strains and biofilm infections; TNBi-1, a narrow spectrum novel small molecule drug for H. pylori infection; TNBi-2, broad spectrum multi-targeting small molecule drug for Nontuberculous mycobacterial pulmonary disease (NTM-PD); and TNBm-1, a broad spectrum bifunctional small molecule drug for metabolic disease. The company was founded in 2012 and is headquartered in Suzhou, China.